Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma
DRKS00020739Phase 2Active, not recruiting
- Sponsor
- Goethe University Frankfurt
- Start
- Jan 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised trial of durvalumab in anal canal carcinoma (SCCA) (2 arms), sponsored by Goethe University Frankfurt. Started Jan 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
anal canal carcinoma (SCCA)
Beyond the preview
Go deeper on DRKS00020739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00020739.